bevacizumab + erlotinib + imatinib

A three-drug anticancer regimen combining the VEGF-A–neutralizing monoclonal antibody bevacizumab, the EGFR tyrosine kinase inhibitor erlotinib, and the PDGFR/KIT/BCR-ABL tyrosine kinase inhibitor imatinib. The rationale was simultaneous inhibition of tumor angiogenesis (VEGF/PDGFR signaling) and tumor cell proliferation/survival (EGFR signaling). In phase I/II studies in metastatic clear cell renal cell carcinoma, the regimen was found tolerable at bevacizumab 10 mg/kg IV every 2 weeks, erlotinib 150 mg PO daily, and imatinib 400 mg PO daily in dose-finding; however, in a larger cohort it produced substantial added toxicity without clear efficacy improvement over bevacizumab + erlotinib, leading investigators to recommend against further development of this triplet in RCC.[1][3][7]

Other names

bevacizumab erlotinib imatinib